Geron (NASDAQ:GERN) initiated with Overweight rating and $4 (210% upside) price target at Cantor Fitzgerald. Shares up 2% premarket.
Blueprint Medicines (NASDAQ:BPMC) initiated with Market Perform rating at Raymond James.
Elanco Animal Health (NYSE:ELAN) upgraded to Neutral at UBS.
QIAGEN (NYSE:QGEN) downgraded to Hold with a $39 (13% upside) price target at Commerzbank.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.